In New England Journal of Medicine editorial, Fred Hutchinson Cancer Research Center’s Dr. Fred Appelbaum argues adult stem cells harvested from bone marrow rather than blood of unrelated donors are best for reducing graft-vs.-host disease risk
Kiem Lab's Korashon Watts explores cord blood stem cell expansion; lauded by American Society of Gene & Cell Therapy
May 21, 2012
| By Colleen Steelquist
Dr. Korashon Watts of the Fred Hutchinson Cancer Research Center Clinical Research Division recently won an Excellence in Research award from the American Society of Gene & Cell Therapy. Her abstract, focused on cord blood stem cell expansion, was selected as one of the top six submitted by a postdoctoral fellow or student for the ASGCT annual meeting in Philadelphia earlier this month.
Hans-Peter Kiem and colleagues find chemo-resistant genes may enable safer, more effective treatment for brain cancer patients
May 23, 2011
| By Dean Forbes
Chemotherapy kills cancer cells, but its toxic effects on normal cells such as bone marrow and blood cells limits its use. Fred Hutchinson Cancer Research Center researchers have found a possible approach to reduce this toxicity: modify the bone marrow cells with a gene that makes them resistant to chemotherapy.
Identification, isolation of adult cells may lead to breast tissue regeneration, new cancer drug targets
Sept. 7, 2010
| By Kristen Woodward
Researchers at the Fred Hutchinson Cancer Research Center are the first to identify and isolate adult mammary stem cells in mice. Long-term implications of this research may include the use of such cells to regenerate breast tissue, provide a better understanding of the role of adult stem cells in breast cancer development, and develop potential new targets for anti-cancer drugs.
Award targets need for glioblastoma therapies, disease model
Aug. 30, 2010
| By Colleen Steelquist
Dr. Patrick Paddison of the Human Biology Division of the Fred Hutchinson Cancer Research Center was recently awarded $148,000 by Accelerate Brain Cancer Cure to identify and develop combination therapies for glioblastoma, the most common and most aggressive form of brain cancer in adults.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.